AptarGroup Q2 Earnings Call Highlights

4 weeks ago 4

MarketBeat

Fri, July 31, 2026 astatine 11:04 AM CDT 7 min read

Key Points

Interested successful AptarGroup, Inc.? Here are 5 stocks we similar better.
AptarGroup reported grounds second-quarter income of astir $1 billion, up 6% twelvemonth implicit year, portion adjusted EPS of $1.42 exceeded guidance. However, adjusted EBITDA fell 3% and the borderline declined to 20.7% amid weaker exigency medicine sales, operating challenges and higher costs.
Pharma remained the strongest area, with halfway income up 8% excluding the anticipated exigency medicine decline, supported by user healthcare, injectables and request tied to GLP-1 therapies and biologics. Beauty and Closures besides posted income growth, but some faced important borderline unit from little volumes, unfavorable premix and accumulation costs.
Aptar forecast third-quarter adjusted EPS of $1.45 to $1.53 and expects maturation crossed each 3 segments. CEO Stephan Tanda volition discontinue aboriginal this year, with Gael Touya scheduled to go CEO connected Sept. 1 and absorption connected profitable growth, execution and superior allocation.

AptarGroup (NYSE:ATR) reported second-quarter income maturation crossed each of its 3 segments and adjusted net per stock supra its guidance range, supported by stronger-than-expected show successful its Pharma business. The institution besides said President and CEO Stephan Tanda volition discontinue aboriginal this year, with President and CEO Designate Gael Touya acceptable to presume the CEO relation connected Sept. 1.

Reported second-quarter income accrued 6% to astir $1 billion, a quarterly record, portion halfway sales, which exclude currency effects and acquisitions, roseate 1% from a twelvemonth earlier. Adjusted EBITDA declined 3% to $213 million, and adjusted EBITDA borderline fell to 20.7% from 22.6% successful the prior-year period. Adjusted EPS was $1.42, compared with $1.68 a twelvemonth earlier astatine comparable speech rates.

→ Why SK hynix Could Be the Best AI Chip Stock to Buy Now

Chief Financial Officer Vanessa Kanu said the net diminution reflected little exigency medicine income successful Pharma, operating challenges successful Beauty and Closures, higher depreciation and amortization related to investments and acquisitions, and higher involvement expense.

Pharma Growth Excluding Emergency Medicine

Pharma halfway income roseate 1% successful the quarter, affected by an anticipated diminution successful exigency medicine sales. Aptar expects exigency medicine income to diminution by astir $65 cardinal during fiscal 2026. Kanu said astir two-thirds of that headwind occurred during the archetypal half, with astir of it occurring successful the 2nd quarter. The remaining information is expected chiefly successful the 3rd quarter, with the year-over-year interaction expected to abate by the 4th quarter.

Read Entire Article